WHO ICTRP trial
Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after…
JPRN-UMIN000004219 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000004219 |
|---|---|
| Public title | Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after progression on bevacizumab with oxaliplatine-based chemotherapy in patients with metastatic colorectal cancer whose KRAS status are investigated. |
| Scientific title | Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after progression on bevacizumab with oxaliplatine-based chemotherapy in patients with metastatic colorectal cancer whose KRAS status are investigated. - KOBE BBP(bevacizumab beyond progression) study |
| Primary sponsor | Hyogo Cancer Center, Dept. of Gastrointestinal and Hepatobiliary Oncology |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase II |
| Countries | Japan |
| Conditions | Recurrent or metastatic colorectal cancer |
| Interventions | Treatment is administered every 2 weeks until evidence of progression, unacceptable toxicity or patient refusal. During the treatment, image assessment is repeated every 2 months at least. |
| Registration date | Sep 16, 2010 |
| Target size | 40 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: